Paclitaxel / CDK1 Cancer Research Results

PacT, Paclitaxel: Click to Expand ⟱
Features:
Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.


Paclitaxel – Cancer Pathway Matrix

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization → Mitotic arrest Mitotic progression ↓; spindle dynamics impaired; cell division blocked Proliferating normal cells affected R, G Core cytotoxic mechanism Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2 Spindle assembly checkpoint activation Prolonged mitotic arrest → mitotic catastrophe or apoptosis Checkpoint stress in dividing tissues R, G Mitotic stress execution Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3 Intrinsic apoptosis (mitochondrial pathway) Caspase activation ↑; BAX/mitochondrial signaling engaged (context) Limited unless stressed G Cell death execution Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4 ROS generation (secondary) ROS ↑ (context-dependent); oxidative stress amplification Oxidative stress possible in sensitive tissues R, G Stress amplifier ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5 Nrf2 antioxidant response (adaptive) Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential Protective antioxidant signaling G Adaptive resistance axis Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6 Drug resistance mechanisms P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring — G Treatment failure driver Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7 Myelosuppression — Neutropenia risk ↑ G Dose-limiting toxicity Bone marrow suppression is a primary clinical constraint.
8 Peripheral neuropathy — Sensory neuropathy risk ↑ G Dose-limiting toxicity Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)



CDK1, Cyclin-dependent kinase 1: Click to Expand ⟱
Source:
Type:
CDK1, (Cyclin-dependent kinase 1) same as p34 (cdc2) kinase activity
Mitotic Gatekeeper, Essential Cell-Cycle Engine, and Therapeutic Vulnerability
Cell cycle control to gene expression regulation and apoptosis, CDK1 is intimately involved in many cellular events that are vital for cell survival.
CDK1 is a significant biomarker in various cancers, with its overexpression often correlating with aggressive tumor characteristics and poor prognosis. Targeting CDK1 may offer therapeutic potential, especially in cancers where its expression is linked to unfavorable outcomes.
Scientific Papers found: Click to Expand⟱
4929- PEITC,  PacT,    Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
ChemoSen↑, Apoptosis↑, TumCCA↑, eff↑, CDK1↓, Bcl-2↓, BAX↑, cl‑PARP↑, SAL↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

SAL↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: CDK1, Cyclin-dependent kinase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:182  Target#:382  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page